Evidence map›Paper›PMID 42733068›Full record

ArticleSignal transduction and targeted therapy2026

IFNAR1-dependent metabolic circuit drives pathogenic neutrophil activation in chronic mucosal inflammation.

Cecilia Pessoa Rodrigues, Raquel R Calçada, Mafalda Arnaud, Lukas Kaltenbach, Mika Manser, Anja Scheidegger, Leon Sidney Strauss, Alina Gavrilov, Sharang Kulkarni, Ece Yildiz and 11 more

Abstract read
In one paragraph

Article in Signal transduction and targeted therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Cecilia Pessoa RodriguesRoche Pharma Research and Early Development, Cardiovascular, Metabolism and Immunology (CMI), Roche Innovation Center Basel, Basel, Switzerland.ORCID http://orcid.org/0000-0001-8617-6565
Raquel R CalçadaRoche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, Basel, Switzerland.
Mafalda ArnaudRoche Pharma Research and Early Development, Cardiovascular, Metabolism and Immunology (CMI), Roche Innovation Center Basel, Basel, Switzerland.
Lukas KaltenbachRoche Pharma Research and Early Development, Cardiovascular, Metabolism and Immunology (CMI), Roche Innovation Center Basel, Basel, Switzerland.
Mika ManserRoche Pharma Research and Early Development, Cardiovascular, Metabolism and Immunology (CMI), Roche Innovation Center Basel, Basel, Switzerland.
Anja ScheideggerRoche Pharma Research and Early Development, Cardiovascular, Metabolism and Immunology (CMI), Roche Innovation Center Basel, Basel, Switzerland.
Leon Sidney StraussRoche Pharma Research and Early Development, Cardiovascular, Metabolism and Immunology (CMI), Roche Innovation Center Basel, Basel, Switzerland.
Alina GavrilovRoche Pharma Research and Early Development, Cardiovascular, Metabolism and Immunology (CMI), Roche Innovation Center Basel, Basel, Switzerland.
Sharang KulkarniRoche Pharma Research and Early Development, Cardiovascular, Metabolism and Immunology (CMI), Roche Innovation Center Basel, Basel, Switzerland.
Ece YildizRoche Pharma Research & Early Development, Strategy, Portfolio and Operations Organisation, 360 Labs, Roche Cell and Organoid Biorepository, Roche Innovation Center Basel.F. Hoffmann-La Roche Ltd., Basel, Switzerland.
Daniela LiberatiRoche Pharma Research & Early Development, Strategy, Portfolio and Operations Organisation, 360 Labs, Roche Cell and Organoid Biorepository, Roche Innovation Center Basel.F. Hoffmann-La Roche Ltd., Basel, Switzerland.
Mairene Coto-LlerenaRoche Pharma Research & Early Development, Strategy, Portfolio and Operations Organisation, 360 Labs, Roche Cell and Organoid Biorepository, Roche Innovation Center Basel.F. Hoffmann-La Roche Ltd., Basel, Switzerland.
Tamara HoeningRoche Pharma Research and Early Development, Cardiovascular, Metabolism and Immunology (CMI), Roche Innovation Center Basel, Basel, Switzerland.
Markus Martin KrambergRoche Pharma Research and Early Development, Cardiovascular, Metabolism and Immunology (CMI), Roche Innovation Center Basel, Basel, Switzerland.
Julian BehrRoche Pharma Research and Early Development, Cardiovascular, Metabolism and Immunology (CMI), Roche Innovation Center Basel, Basel, Switzerland.
Anna MechlingRoche Pharma Research and Early Development, Cardiovascular, Metabolism and Immunology (CMI), Roche Innovation Center Basel, Basel, Switzerland.
Marvin HeringRoche Pharma Research and Early Development, Cardiovascular, Metabolism and Immunology (CMI), Roche Innovation Center Basel, Basel, Switzerland.
Kara G LassenRoche Pharma Research and Early Development, Cardiovascular, Metabolism and Immunology (CMI), Roche Innovation Center Basel, Basel, Switzerland.
Oliver SoehnleinInstitute of Experimental Pathology, Center for Molecular Biology of Inflammation, University of Münster, Münster, Germany.ORCID http://orcid.org/0000-0002-7854-0694
Emma DoranRoche Pharma Research and Early Development, Cardiovascular, Metabolism and Immunology (CMI), Roche Innovation Center Basel, Basel, Switzerland. emma.doran@roche.com.ORCID http://orcid.org/0009-0000-6457-0641
Daniel Regan-KomitoRoche Pharma Research and Early Development, Cardiovascular, Metabolism and Immunology (CMI), Roche Innovation Center Basel, Basel, Switzerland. daniel.regan-komito@roche.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neutrophils are double-edged effectors of the innate immune system: while essential for host defense, they can drive significant tissue damage in the context of chronic inflammatory diseases. Identifying strategies to selectively dampen their pathogenic functions without compromising antimicrobial immunity remains a major clinical challenge. Here, we define a conserved IFNAR1-driven circuit mediated by iron homeostasis that sustains neutrophil pathogenicity across distinct mucosal tissues. Using single-cell transcriptomics and a CRISPR-based functional screen, we identified the mitochondrial iron transporter Mitoferrin-1 (SLC25A37) as a key regulator of neutrophil inflammatory programming. Mechanistically, our data indicate that Mitoferrin-1 mediates a feedforward loop in which NET-derived histones activate toll-like receptor 9 (TLR9), which in turn sustains IFN-α/IFNAR1 signaling, rewires mitochondrial metabolism, and ultimately drives tissue damage through markedly increased of NETosis, reactive oxygen species production, and degranulation. Notably, this IFNAR1-driven inflammatory circuit operates entirely independently of antimicrobial function, as pharmacological IFNAR1 blockade fully preserves phagocytic activity against bacterial pathogens in vivo. Targeting this pathway selectively attenuates neutrophil-driven inflammation in both murine models of colitis and acute lung injury, as well as in primary human intestinal organoid systems. Together, these findings identify a targetable metabolic node for selectively disarming pathogenic neutrophil responses in the setting of chronic inflammatory disease.

Indexed as

InflammationNeutrophil ActivationNeutrophilsReceptor, Interferon alpha-betaAnimalsChronic DiseaseHumansMiceMice, KnockoutSignal TransductionToll-Like Receptor 9Ifnar1 protein, mouseReceptor, Interferon alpha-betaToll-Like Receptor 9

Identifiers

PMID42733068
PMCPMC13572512

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.